ZA200405414B - Cancer treatment. - Google Patents
Cancer treatment. Download PDFInfo
- Publication number
- ZA200405414B ZA200405414B ZA200405414A ZA200405414A ZA200405414B ZA 200405414 B ZA200405414 B ZA 200405414B ZA 200405414 A ZA200405414 A ZA 200405414A ZA 200405414 A ZA200405414 A ZA 200405414A ZA 200405414 B ZA200405414 B ZA 200405414B
- Authority
- ZA
- South Africa
- Prior art keywords
- therapeutic system
- antibody
- treatment
- chemotherapeutic agent
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 57
- 238000011282 treatment Methods 0.000 title claims description 54
- 201000011510 cancer Diseases 0.000 title claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 35
- 230000001225 therapeutic effect Effects 0.000 claims description 35
- 102000007298 Mucin-1 Human genes 0.000 claims description 33
- 108010008707 Mucin-1 Proteins 0.000 claims description 33
- 229940127089 cytotoxic agent Drugs 0.000 claims description 32
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 9
- 229960004316 cisplatin Drugs 0.000 claims description 9
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 9
- 229960004528 vincristine Drugs 0.000 claims description 9
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 8
- 229960004397 cyclophosphamide Drugs 0.000 claims description 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 8
- 229960005277 gemcitabine Drugs 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 7
- FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical group N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- 206010005081 Bladder squamous cell carcinoma stage unspecified Diseases 0.000 claims 3
- 201000006598 bladder squamous cell carcinoma Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 description 18
- 238000011363 radioimmunotherapy Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000000973 chemotherapeutic effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108010071421 milk fat globule Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- VAOYPHGXHKUTHC-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 VAOYPHGXHKUTHC-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940127130 immunocytokine Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000011258 immunoradiotherapy Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0200657.5A GB0200657D0 (en) | 2002-01-12 | 2002-01-12 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200405414B true ZA200405414B (en) | 2005-06-22 |
Family
ID=9928970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200405414A ZA200405414B (en) | 2002-01-12 | 2004-07-07 | Cancer treatment. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050163707A1 (pt) |
| EP (1) | EP1465661A1 (pt) |
| JP (1) | JP2005520802A (pt) |
| KR (1) | KR20040091623A (pt) |
| CN (1) | CN1638797A (pt) |
| AU (1) | AU2003205813A1 (pt) |
| BR (1) | BR0306809A (pt) |
| CA (1) | CA2472893A1 (pt) |
| GB (2) | GB0200657D0 (pt) |
| IL (1) | IL162814A0 (pt) |
| MX (1) | MXPA04006747A (pt) |
| NO (1) | NO20042850L (pt) |
| PL (1) | PL371419A1 (pt) |
| RU (1) | RU2004124520A (pt) |
| WO (1) | WO2003057250A1 (pt) |
| ZA (1) | ZA200405414B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2629819B1 (fr) * | 1988-04-06 | 1990-11-16 | Rhone Poulenc Sante | Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii |
| GB9019553D0 (en) * | 1990-09-07 | 1990-10-24 | Unilever Plc | Specific binding agents |
| US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
| AU4430701A (en) * | 2000-04-03 | 2001-10-15 | Antisoma Research Limited | Compounds for targeting |
-
2002
- 2002-01-12 GB GBGB0200657.5A patent/GB0200657D0/en not_active Ceased
-
2003
- 2003-01-13 PL PL03371419A patent/PL371419A1/xx unknown
- 2003-01-13 WO PCT/GB2003/000105 patent/WO2003057250A1/en not_active Application Discontinuation
- 2003-01-13 RU RU2004124520/14A patent/RU2004124520A/ru not_active Application Discontinuation
- 2003-01-13 AU AU2003205813A patent/AU2003205813A1/en not_active Abandoned
- 2003-01-13 CA CA002472893A patent/CA2472893A1/en not_active Abandoned
- 2003-01-13 CN CNA038047748A patent/CN1638797A/zh active Pending
- 2003-01-13 US US10/501,568 patent/US20050163707A1/en not_active Abandoned
- 2003-01-13 IL IL16281403A patent/IL162814A0/xx unknown
- 2003-01-13 EP EP03702690A patent/EP1465661A1/en not_active Withdrawn
- 2003-01-13 MX MXPA04006747A patent/MXPA04006747A/es not_active Application Discontinuation
- 2003-01-13 KR KR10-2004-7010824A patent/KR20040091623A/ko not_active Application Discontinuation
- 2003-01-13 GB GB0300600A patent/GB2383538B/en not_active Expired - Fee Related
- 2003-01-13 BR BR0306809-9A patent/BR0306809A/pt not_active Application Discontinuation
- 2003-01-13 JP JP2003557607A patent/JP2005520802A/ja active Pending
-
2004
- 2004-07-06 NO NO20042850A patent/NO20042850L/no unknown
- 2004-07-07 ZA ZA200405414A patent/ZA200405414B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB0300600D0 (en) | 2003-02-12 |
| AU2003205813A1 (en) | 2003-07-24 |
| RU2004124520A (ru) | 2005-03-20 |
| IL162814A0 (en) | 2005-11-20 |
| GB2383538B (en) | 2003-11-19 |
| CN1638797A (zh) | 2005-07-13 |
| GB0200657D0 (en) | 2002-02-27 |
| WO2003057250A1 (en) | 2003-07-17 |
| KR20040091623A (ko) | 2004-10-28 |
| US20050163707A1 (en) | 2005-07-28 |
| JP2005520802A (ja) | 2005-07-14 |
| MXPA04006747A (es) | 2006-01-30 |
| CA2472893A1 (en) | 2003-07-17 |
| PL371419A1 (en) | 2005-06-13 |
| BR0306809A (pt) | 2004-12-07 |
| NO20042850L (no) | 2004-08-26 |
| GB2383538A (en) | 2003-07-02 |
| EP1465661A1 (en) | 2004-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU782994B2 (en) | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | |
| Schwartzberg | Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma | |
| Litvak-Greenfeld et al. | Risks and untoward toxicities of antibody-based immunoconjugates | |
| AU2006332212B2 (en) | Combination therapy using anti-EGFR and anti-HER2 antibodies | |
| US5165922A (en) | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy | |
| JP4576005B2 (ja) | 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ | |
| EP0252741B1 (en) | Use of a monoclonal antibody against the 17-1A antigen for the manufacture of a medicament for the treatment of a gastrointestinal tumor | |
| WO2021182573A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JP2021525735A (ja) | 抗ｃｄ３７免疫コンジュゲート投薬レジメン | |
| EP1684770B1 (en) | Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer | |
| Dillman et al. | Unique aspects of supportive care using monoclonal antibodies in cancer treatment | |
| Buchegger et al. | Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice | |
| TWI817190B (zh) | 抗ｃ-Ｍｅｔ抗體藥物偶聯物及其應用 | |
| JPH03504854A (ja) | 細胞毒素療法 | |
| JP6368811B2 (ja) | 放射線感受性を調節するためのｈｅｒ３阻害剤 | |
| ZA200405414B (en) | Cancer treatment. | |
| KR101637689B1 (ko) | 아토르바스타틴을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 | |
| Rickmann | Naxitamab. Humanized anti-GD2 ganglioside monoclonal antibody, Treatment of high-risk neuroblastoma | |
| KR102075724B1 (ko) | 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 | |
| DUFFY et al. | Monoclonal Antibodies Including Antibody–Drug Conjugates, Immunoconjugates, and Cytokine-Directed Agents | |
| KR20230111071A (ko) | 렌바티닙을 포함하는 암의 방사면역치료 보조제 | |
| TW202306588A (zh) | 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途 | |
| AU650080B2 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
| Mach | Combined Radioimmunotherapy and Radiotherapy of Human Colon Carcinoma Grafted in Nude Mice1 | |
| Weaver | Zelboraf® Active in Hairy Cell Leukemia That Has Progressed After Other Treatment |